

You are the capacity adviser to VIB, an Indian vaccine manufacturer racing to be ready for Novishield, a COVID-era vaccine that has not yet been approved. Each round you decide how many plants to build, where every plant is ₹50 billion of dedicated capacity that pays off only if both approval and demand arrive. Approval is a probability and demand is only a set of disagreeing forecasts. Build too little and you strand a market you could have served; build too much and the fixed cost sinks you. You are judged on the profit your commitments earn once the truth is revealed. What the reveal shows is that the forecast-optimal build and the profitable one are rarely the same, and that deep uncertainty rewards restraint.